Insider Transactions in Q4 2024 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
742
-2.93%
|
$35,616
$48.61 P/Share
|
|
Dec 16
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+2.85%
|
$5,194
$7.37 P/Share
|
|
Dec 11
2024
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,872
+10.72%
|
$83,104
$7.37 P/Share
|
|
Dec 11
2024
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
1,780
-4.42%
|
$89,000
$50.42 P/Share
|
|
Dec 10
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.99%
|
$365,000
$50.64 P/Share
|
|
Dec 10
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.12%
|
$37,100
$7.96 P/Share
|
|
Dec 03
2024
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,607
+9.64%
|
-
|
|
Dec 03
2024
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,536
-3.94%
|
$78,336
$51.51 P/Share
|
|
Dec 03
2024
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,530
+3.99%
|
-
|
|
Dec 03
2024
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-1.5%
|
$13,923
$51.51 P/Share
|
|
Dec 03
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+3.3%
|
-
|
|
Dec 03
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,028
-1.75%
|
$103,428
$51.51 P/Share
|
|
Dec 03
2024
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,353
+4.47%
|
-
|
|
Dec 03
2024
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,351
-2.01%
|
$68,901
$51.51 P/Share
|
|
Dec 03
2024
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,059
+2.72%
|
-
|
|
Dec 03
2024
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,843
-1.43%
|
$297,993
$51.51 P/Share
|
|
Dec 02
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$250,000
$50.76 P/Share
|
|
Dec 02
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Nov 26
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-3.1%
|
$365,000
$50.15 P/Share
|
|
Nov 26
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.26%
|
$37,100
$7.96 P/Share
|
|
Nov 25
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
742
-2.93%
|
$37,100
$50.0 P/Share
|
|
Nov 25
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+2.85%
|
$5,194
$7.37 P/Share
|
|
Nov 18
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$250,000
$50.55 P/Share
|
|
Nov 18
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Nov 12
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
6,342
-2.66%
|
$367,836
$58.48 P/Share
|
|
Nov 12
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.22%
|
$37,100
$7.96 P/Share
|
|
Nov 01
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$255,000
$51.63 P/Share
|
|
Nov 01
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Oct 30
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-3.02%
|
$372,300
$51.92 P/Share
|
|
Oct 30
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.16%
|
$37,100
$7.96 P/Share
|
|
Oct 28
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
4,452
-15.35%
|
$231,504
$52.25 P/Share
|
|
Oct 28
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,452
+13.3%
|
$31,164
$7.37 P/Share
|
|
Oct 15
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.97%
|
$394,200
$54.19 P/Share
|
|
Oct 15
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.09%
|
$37,100
$7.96 P/Share
|
|
Oct 09
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$275,000
$55.61 P/Share
|
|
Oct 09
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Oct 01
2024
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
118
+0.48%
|
$6,136
$52.6 P/Share
|
|
Oct 01
2024
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
237
+0.93%
|
$12,324
$52.6 P/Share
|
|
Oct 01
2024
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
403
+1.04%
|
$20,956
$52.6 P/Share
|
|
Oct 01
2024
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
237
+1.48%
|
$12,324
$52.6 P/Share
|
|
Oct 01
2024
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
118
+0.51%
|
$6,136
$52.6 P/Share
|
|
Oct 01
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.96%
|
$379,600
$52.1 P/Share
|
|
Oct 01
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.09%
|
$37,100
$7.96 P/Share
|